Abstract Details

Title Early detection of silent brain function changes in multiple sclerosis using magnetoencephalography (MEG): Towards an imaging biomarker

Topic Multiple Sclerosis

Presentation(s) P11 - Poster Session 11 (11:45 AM-12:45 PM)

Poster/Presentation
Number 3-004

Objective The objective are to identify imaging biomarkers that differentiate MS patient from normal control subjects using MEG.

Background MEG is a noninvasive functional brain imaging technique that measures the magnetic brain waves arising from neuronal activity during rest or a cognitive task. MEG may help detect functional changes or abnormalities in MS patients early in the disease course.

Design/Methods In this single-center prospective pilot study, the resting state MEG data from 6 patients with MS were compared to 6 control subjects. MEG data were filtered into 4 different frequency bands: theta 4-7Hz, alpha 8-13HZ, beta 14-30Hz, and gamma 30-85 Hz. Network brain activity for each frequency band was mapped for connectivity strength across 27 regions in each hemisphere, resulting in 1431 pairings in the brain. A t-test was conducted to assess group differences in average coherence values for each pair of brain regions (N= 1,431). A P-value was produced for each region pair. The false discovery rate (FDR) was used to adjust for multiple testing. Only the most statistically significant connections between the control group and the patient group were further analyzed. These were based on a p-value of less than 0.05.

Results During the resting state, the MS patients had more hyperexcited/coherent connected activity in the frontal to occipital regions, while the control subjects had more coherent connections in the frontal to temporal, frontal to parietal as well as the parietal to the temporal areas.

Conclusions

MEG could detect apparent differences in active networks during rest in patients with MS compared to controls. This will have future applications to improve or tailor treatments during the early neuronal dysfunction that could lead to functional and cognitive disabilities in patients with MS. The limitation of our study is the small sample size. The complete data analysis of 10 patients will be presented at AAN 2023.

Authors/Disclosures
Mouhamad Hammami PRESENTER	Mr. Hammami has nothing to disclose.
	No disclosure on file
Anza B. Memon, MD, FAAN (Wayne State University, SOM, Detroit, MI)	Dr. Memon has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Inlightened. Dr. Memon has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Connected Research. Dr. Memon has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutic . The institution of Dr. Memon has received research support from Genentech. The institution of Dr. Memon has received research support from TG Therapeutics.
Susan M. Bowyer, PhD (Henry Ford Hospital)	Dr. Bowyer has nothing to disclose.

��ɫ��

��ɫ��